Kwality Pharmaceuticals Ltd (KPL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Kwality Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
EU-GMP Approval from Hungary for Cephalosporin and Oncology Facilities
Others (Uncategorized) · 04 Nov 2026, 6:29 pm
Kwality Pharmaceuticals Secures Hungarian EU-GMP Approval for Cephalosporin and Oncology Units Kwality Pharmaceuticals Ltd. has secured EU-GMP approval from Hungary for its Cephalosporin and Oncology manufacturing facilities, complementing its existing EU-GMP certification from Bulgaria. This regulatory milestone significantly broadens the company’s certified capacity across specialized pharmaceutical segments and strengthens its competitive position in highly regulated, high-value global markets. The approval is expected to drive international business growth by unlocking new licensing opportunities and accelerating foreign product registrations.
Acquisition of Land for Manufacturing Expansion at Amritsar
Others (Uncategorized) · 19 Oct 2026, 8:14 pm
Kwality Pharmaceuticals Acquires Land for Amritsar Manufacturing Capacity Expansion Kwality Pharmaceuticals acquired 4 acres of land adjacent to its existing Amritsar, Punjab facility to develop a fully automated, EU GMP-compliant manufacturing unit. The expansion will feature 4 injectable lines and over 6 lines for tablets, capsules, ophthalmic, and other oral solid dosage formulations. Aimed at meeting rising demand, future launches, and bioequivalence opportunities, project completion is targeted for Q4 FY'28, with full operations slated for Q2 FY'29.
Regularization of appointment of Mr Swanith Kapoor as Director and reappointment of Mr Aditya Arora as WTD of the company
Change in Management · 03 Sept 2026, 4:59 am
Kwality Pharmaceuticals Approves Key Board Appointments at 43rd AGM At its 43rd AGM on 31st Aug'26, Kwality Pharmaceuticals' shareholders approved two key board appointments. Mr. Swanith Kapoor was regularized as a Non-Executive Independent Director for a five-year term spanning 2nd Jun'26 to 1st Jun'31. Furthermore, Mr. Aditya Arora was reappointed as Whole Time Director for five years, effective 30th Sep'26 to 29th Sep'31. Mr. Arora continues to oversee production, quality control, and regulatory filings. Both directors are cleared by SEBI to hold office, securing leadership continuity for the firm's operational and governance frameworks.
SCRUTINIZER REPORT OF AGM E-VOTING IS ATTACHED
Annual General Meeting · 03 Sept 2026, 4:42 am
Proceedings of 43rd Annual General Meeting attached herewith.
Annual General Meeting · 31 Aug 2026, 11:57 pm
Outcome of Investors/Analysts Meeting held on August 10, 2026
Audio / Video · 12 Aug 2026, 9:19 pm
Kwality Pharma Updates Investors on Business Operations Kwality Pharmaceuticals (BSE: 539997) held a virtual investor knowledge session on 10th Aug'26, organized by Go India Advisors. Management discussed the company's business operations, performance, and outlook using only publicly available information. The company confirmed that no unpublished price-sensitive information (UPSI) was shared during the meeting. An audio/video recording of the interaction has been made available on the company's website for reference.
Transcript of Earnings Conference Call - Q1FY27
Transcript · 12 Aug 2026, 9:04 pm
Transcript of Earnings Conference Call - Q1FY27
Transcript · 12 Aug 2026, 9:03 pm
Investor Presentation for quarter ended June 30, 2026.
Investor Presentation · 10 Aug 2026, 6:10 pm
Kwality Pharma Raises FY27 Guidance on Strong Q1FY27 Performance and Growth Visibility Kwality Pharmaceuticals reported strong Q1FY27 results, with revenue at ₹162.4 Cr (+45.7% YoY) and PAT at ₹25.7 Cr (+119.3% YoY). EBITDA margin expanded to 25.3% from 21.9% in Q1FY26. Following this performance, the company raised its FY27 guidance. Revenue is now projected at ₹700+ Cr (up from ₹650 Cr), targeting 39%+ YoY growth. PAT guidance was increased to ₹109+ Cr (from ₹100 Cr), with margins expanding to ~15.5%+. The upgrade reflects higher growth visibility, stronger operating leverage, and an improved product mix.
Financial Results for Quarter Ended June 30, 2026.
Financial Result · 10 Aug 2026, 5:57 pm
Kwality Pharma Q1FY27 Results: Strong Revenue Growth and Margin Expansion Kwality Pharmaceuticals reported strong Q1FY27 results with consolidated revenue up 46% YoY to ₹162 crore. EBITDA grew 13% YoY to ₹41 crore, with margins expanding to 25.3% from 21.9% in Q1FY26 due to operating leverage. PAT surged 119% YoY to ₹26 crore, and PAT margin improved sharply to 16% from 11%. Following the strong performance, management raised FY27 guidance for revenue to ₹700+ crore, EBITDA to ₹189-196+ crore, and PAT to ₹109+ crore. Key operational highlights include R&D advancements and biologics approvals.
Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 2015
Outcome · 10 Aug 2026, 5:39 pm
Kwality Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 16,235 (+45.6% YoY | +3.3% QoQ) ■ EBITDA: 4,102 (+69.7% YoY | +5.8% QoQ) ■ EBITDA Margin (%): 25.3 (+358 bps YoY | +59 bps QoQ) ■ PAT: 2,562 (+114.9% YoY | +1.3% QoQ) ■ EPS (INR): 24.7 (+114.9% YoY | +1.2% QoQ)
NOTICE OF 43RD AGM IS ENCLOSED
Annual General Meeting · 10 Aug 2026, 5:04 am
Pursuant to Regulations 30 and 34 of the SEBI (LODR) Regulations, 2015, as amended ('' Listing Regulations''), please find attached herewith the Annual Report of the Company for the FY ....
Others (Uncategorized) · 10 Aug 2026, 4:58 am
Intimation of Book Closure.
Others (Uncategorized) · 09 Aug 2026, 2:02 am
Kwality Pharmaceuticals Announces Book Closure for 43rd AGM Kwality Pharmaceuticals (Scrip: 539997) has announced its book closure from 25 Aug'26 to 31 Aug'26 for its 43rd Annual General Meeting (AGM). The record date (cut-off date) to determine shareholder eligibility for e-voting at the AGM is set for 24 Aug'26. The company had previously set a cut-off date of 31 Jul'26 for the purpose of sending the notice to shareholders.
Intimation of 43rd AGM
Annual General Meeting · 09 Aug 2026, 1:59 am
This is to inform you, pursuant to Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Board of Directors ....
Others (Uncategorized) · 09 Aug 2026, 1:55 am
Intimation of Earnings Conference Call for Q1 FY 2026-27
Intimation · 10 Aug 2026, 4:00 pm
Kwality Pharmaceuticals to Host Q1 FY27 Earnings Call on Aug 10, 2026 Kwality Pharmaceuticals Limited (BSE: 539997) has scheduled its Q1 FY27 earnings conference call for Monday, 10th Aug'26, at 4:00 PM IST. The call, hosted by Go India Advisors, will feature key management including Managing Director Mr. Ramesh Kumar and Director & CFO Mr. Aditya Arora. Investors can join via the provided universal dial-in numbers after completing the mandatory pre-registration.
Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve the Standalone and ....
Intimation · 10 Aug 2026, 5:30 am
Kwality Pharma Board Meeting on Aug 10, 2026 for Q1FY27 Results Kwality Pharmaceuticals (BSE: 539997) has scheduled a Board of Directors meeting for 10 Aug'26 at 10:30 A.M. The agenda includes the consideration and approval of the standalone and consolidated unaudited financial results for the quarter ended 30 Jun'26. In connection with this, the trading window for designated persons will remain closed until 48 hours after the results are declared on 10 Aug'26. This meeting will determine the company's financial performance for the first quarter of fiscal year 2027.
Kwality Pharmaceuticals receives CDSCO Nod to Initiate Preclinical Pilot Batches of Pembroluzimab
Others (Uncategorized) · 24 Jul 2026, 3:36 pm
Kwality Pharma Receives CDSCO Approval for Pembroluzimab Preclinical Batches Kwality Pharmaceuticals received permission on 24 Jul'26 from the Central Drugs Standard Control Organization (CDSCO) to manufacture pilot batches of Pembroluzimab. This key approval allows the company to initiate preclinical studies, transitioning the product from the R&D stage. The company aims to be among the first generic manufacturers to launch the biologic drug following the reference product's patent expiry. This marks a significant milestone in its biologics development program, contingent on successful trials and further regulatory approvals.
Resignation of Mr. Kartik Kapur, Independent Director of the Company.
Change in Management · 02 Jun 2026, 10:56 pm
Kwality Pharmaceuticals Announces Board Changes Kwality Pharmaceuticals has appointed Mr. Swanith Kapoor as an Additional (Non-Executive, Independent) Director for a five-year term, effective from 02 Jun'26 to 01 Jun'31, subject to shareholder approval. Concurrently, Mr. Kartik Kapur has resigned as an Independent Director, effective 02 Jun'26, citing other professional commitments. Mr. Kapur confirmed no other material reasons for his resignation. These changes signify a key transition in the company's board composition, introducing new legal and corporate law expertise through Mr. Kapoor's appointment.
Appointment of Mr. Swanith Kapoor as Additional (Non-Executive, Independent) Director and Resignation of Mr. Kartik Kapur, Independent Director of the Company.
Change in Management · 02 Jun 2026, 10:53 pm
Kwality Pharmaceuticals Announces Board Changes with Director Appointment and Resignation Kwality Pharmaceuticals has appointed Mr. Swanith Kapoor as an Additional (Non-Executive, Independent) Director for a five-year term, effective from Jun 02, 26, to Jun 01, 31, subject to shareholder approval. Concurrently, Mr. Kartik Kapur resigned as an Independent Director, effective from the close of business on Jun 02, 26, citing other professional commitments. Mr. Kapur confirmed no other material reasons for his departure and holds no directorships in other listed companies. The changes ensure a smooth transition in board composition.
Audio recording of quarterly earning conference call
Audio / Video · 28 May 2026, 4:50 pm
Kwality Pharma Reports Strong FY26 Growth and Outlines Aggressive FY27-FY29 Targets Kwality Pharmaceuticals reported strong FY26 results with revenue up 36% to INR503 crores and PAT growing 69% to INR67 crores, driven by improved operational efficiency. Q4FY26 revenue rose 35.8% to INR157.1 crores. Management guides for FY27 revenue of INR650-700 crores and PAT of INR100 crores. The company targets INR1,000 crores revenue by FY29 with a 30% EBITDA margin, primarily driven by oncology and expansion into regulated markets. An additional INR200 crores in revenue from hormones and biologics is expected by FY29.
Transcript of Earning Conference Call of Q4FY2026.
Transcript · 21 May 2026, 11:59 pm
Investor Presentation for the quarter and year ended 31st March, 2026.
Investor Presentation · 19 May 2026, 5:41 pm
Kwality Pharma FY26: Strong Revenue Growth and Margin Expansion Kwality Pharmaceuticals posted strong FY26 results with revenue up 36% YoY to ₹503.1 Cr and PAT rising 72% YoY to ₹67.4 Cr. EBITDA margin expanded to 24.0% from 21.6% in FY25. For Q4FY26, revenue grew 36.2% YoY to ₹157.1 Cr, while PAT surged 77.2% YoY to ₹25.3 Cr. The company targets ₹650 Cr revenue in FY27, driven by EU-GMP readiness, capacity expansion in oncology and biologics, and commercializing its first biologic, Erythropoietin, in H1FY27.
Audited Financial Results for the quarter and year ended 31st March, 2026.
Financial Result · 19 May 2026, 5:34 pm
KWALITY PHARMACEUTICALS LIMITED - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakhs) ■ Revenue: 15711 (+35.8% YoY | +27.3% QoQ) ■ EBITDA: 3876 (+49.7% YoY | +29.4% QoQ) ■ EBITDA Margin (%): 24.7 (+229 bps YoY | +41 bps QoQ) ■ PAT: 2530 (+74.6% YoY | +58.0% QoQ) ■ EPS (INR): 24.4 (+74.8% YoY | +58.2% QoQ)